Transplant;Failure,Kidney Clinical Trial
Official title:
Non-invasive Blood Test to Diagnose Acute Rejection After Pancreas and Kidney Transplantation: Pancreas and Renal Rejection Diagnosis Using Circulating Donor-derived Cell-free DNA in Peripheral Blood
Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of interstitial fibrosis (IF) and tubular atrophy (TA) seen in biopsy specimens. Here, we will study the utility of dd-cfDNA to predict rejection in pancreas and pancreas-kidney recipients.
+Objective The objective of this prospective observational study is to correlate circulating dd-cfDNA to clinical and sub-clinical acute rejection in pancreas transplant alone (PTA), pancreas after kidney (PAK), and simultaneous pancreas kidney (SPK) allograft recipients. The secondary objective study is to correlate circulating dd-cfDNA to pancreas and kidney function, using Hgb1c, C-peptide and insulin requirement to assess pancreas function, and using serum creatinine and estimated glomerular filtration rate (eGFR) to assess kidney function. The clinical data and specimen collection will also enable future biomarker research. +Study endpoints Serial dd-cfDNA in individuals over time will be correlated with clinical status and outcomes, such as events of allograft dysfunction or biopsy proven rejection. The primary endpoints of the study are: 1. Clinical T cell as well as antibody mediated acute rejection 2. Sub-clinical T cell as well as antibody mediated acute rejection 3. Composite of clinical and sub-clinical T cell as well as antibody mediated acute rejection. The secondary endpoints for the study are: 1. eGFR (estimated Glomerular Filtration Rate [mL/min]): will be derived from serum creatinine level, corrected for variables, using the CKD-RPI (Chronic Kidney Disease Epidemiology Collaboration) equation. 2. Renal allograft injury from BKV (Polyomaviridae polyomavirus) nephritis, CNI (calcineurin inhibitor) toxicity, acute pyelonephritis and recurrent disease confirmed by renal histology. 3. Pancreas allograft function derived from hemoglobin A1c, insulin requirement, and serum c-peptide per SOC 4. Pancreas allograft injury from pancreatitis (all causes, including gastrointestinal dysmotility or viral). 5. Correlate cfDNA levels with presence or absence of delayed graft function (DGF) and subsequent outcomes in a subset of enrolled patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05811468 -
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
|
||
Completed |
NCT03723668 -
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
|
||
Recruiting |
NCT03737604 -
TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
|
Phase 4 | |
Completed |
NCT03765203 -
Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients
|
N/A | |
Completed |
NCT05809440 -
Effectiveness of 20m-MB in KTR Symptom Control
|
N/A | |
Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
Not yet recruiting |
NCT06396702 -
EASE-SOT Pilot Study
|
N/A | |
Recruiting |
NCT03310905 -
Abdominal Wall Transplant
|
N/A | |
Recruiting |
NCT05613010 -
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
|
N/A | |
Recruiting |
NCT06263257 -
The Effect of Mandala Therapy on Anxiety and Comfort in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT04715412 -
Clinical Pharmacy Guided Patient Counselling and Adherence Support on Renal Transplant Recipients
|
N/A | |
Active, not recruiting |
NCT05449496 -
Dietary Intervention to Improve Kidney Transplant Outcomes
|
N/A | |
Not yet recruiting |
NCT06089473 -
Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates
|
N/A | |
Withdrawn |
NCT04473924 -
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
|
Phase 2 | |
Recruiting |
NCT04619732 -
Real-time Monitoring of Kidney Grafts on Hypothermic Machine Perfusion
|
N/A | |
Completed |
NCT03760263 -
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
|
Phase 4 | |
Active, not recruiting |
NCT03380962 -
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03436368 -
Continuous Spinal Anesthesia in Renal Transplantation
|
N/A | |
Not yet recruiting |
NCT03322709 -
Minimally Invasive Kidney Transplantation
|
N/A | |
Recruiting |
NCT03778944 -
Enhancing Renal Graft Function During Donor Anesthesia
|
N/A |